Menter 2009.

Methods	DESIGN Between‐patient Participant delivery ALLOCATION Random Method of randomisation: not reported Concealment: unclear BLINDING Open (blinding NS but product vehicles differ) WITHDRAWAL/DROPOUT Described
Participants	N: 122 Treatment duration: 4 wks; FU: 8 wks LF: 0 (0%) BC: yes Age: 46.5 (14.2SD) Gender (per cent men): 61.1% Duration (yrs): 16.4 (11.50SD) Severity: ODS = 3.06 (0.43SD) (participant demographics based on per‐protocol sample). INCLUSION CRITERIA People aged 18 to 80 with moderate to severe stable plaque psoriasis BSA: 3 to 20% EXCLUSION CRITERIA Known allergy to study ingredients Psoriasis affecting scalp, face, or groin only Area affected required weekly treatment with > 50 g CP spray or > 100 g C‐BD ointment
Interventions	Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination ointment OD (C‐BD) Clobetasol propionate 0.05% spray (CP)
Outcomes	Overall disease severity (ODS) on a 5‐pt scale: clear (0), almost clear, mild, moderate, severe/very severe (4) Based on erythema, scaling, and elevation Investigator Global Assessment (IGA) on a 4‐pt scale (0 to 3): clear (0), mild, moderate, severe (3). Based on per cent BSA affected (extent) rather than signs
Notes	Galderma Laboratories, LP, sponsored the trial. Atrophy was not assessed. Telangiectasia was not assessed. 29 participants were 'non‐compliant' with treatment, but intention‐to‐treat (ITT) analysis included all enrolled participants. The sponsor supplied unpublished data.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	High risk	The trial was open (blinding not reported, but product vehicles differ).
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Low risk	0%
Baseline assessments	Low risk	These were reported.
Baseline comparability demonstrated	Low risk	This was demonstrated.